TABLE 1.
| DRd (N = 302) | VRd (N = 341) | Std. diff. (%) | |
|---|---|---|---|
| Age (years) at the index date, mean ± SD [median] | 75.3 ± 8.9 [75.0] | 74.5 ± 5.0 [74.0] | 10.9* |
| Age ≥ 80 years, n (%) | 77 (25.5) | 74 (21.7) | 9.1 |
| Female, n (%) | 148 (48.9) | 156 (45.8) | 6.4 |
| Race, n (%) | |||
| White | 169 (55.8) | 200 (58.7) | 5.7 |
| Black | 26 (8.8) | 38 (11.3) | 8.4 |
| Asian | 7 (2.2) | 6 (1.9) | 2.5 |
| Other c | 100 (33.2) | 96 (28.2) | 10.8* |
| Ethnicity, n (%) | |||
| Non‐Hispanic | 189 (62.7) | 243 (71.3) | 18.6* |
| Hispanic | 24 (7.9) | 8 (2.3) | 25.7* |
| Other | 5 (1.8) | 3 (0.8) | 8.5 |
| Unknown | 84 (27.6) | 87 (25.5) | 4.8 |
| US geographic region, n (%) | |||
| West | 103 (34.0) | 111 (32.6) | 3.0 |
| South | 86 (28.4) | 103 (30.2) | 3.8 |
| North Central | 52 (17.2) | 67 (19.8) | 6.6 |
| Northeast | 24 (8.1) | 23 (6.7) | 5.3 |
| Unknown | 37 (12.2) | 37 (10.8) | 4.6 |
| Insurance plan type, n (%) | |||
| Medicare | 190 (62.7) | 225 (65.9) | 6.8 |
| Managed care | 52 (17.2) | 67 (19.7) | 6.3 |
| Medicaid | 5 (1.8) | 9 (2.7) | 6.2 |
| Other | 70 (23.0) | 69 (20.3) | 6.6 |
| Unknown | 11 (3.7) | 11 (3.1) | 3.5 |
| Index year, n (%) | |||
| 2019 | 15 (5.0) | 36 (10.6) | 21.1* |
| 2020 | 72 (23.7) | 90 (26.5) | 6.4 |
| 2021 | 94 (30.9) | 104 (30.4) | 1.2 |
| 2022 | 98 (32.5) | 97 (28.5) | 8.7 |
| ISS stage, n (%) | |||
| Stage 1 | 0 (0.0) | 2 (0.7) | 11.6 |
| Stage 2 | 23 (7.6) | 22 (6.6) | 3.9 |
| Stage 3 | 28 (9.1) | 26 (7.7) | 5.3 |
| Not available | 252 (83.3) | 290 (85.1) | 4.9 |
| Quan–CCI d , mean ± SD [median] | 3.8 ± 3.3 [3.0] | 3.6 ± 1.9 [2.0] | 5.4 |
| Malignancies and metastatic solid tumor, n (%) | 55 (18.3) | 53 (15.5) | 7.6 |
| Diabetes without chronic complications, n (%) | 33 (11.0) | 32 (9.4) | 5.6 |
| Peripheral vascular disease, n (%) | 23 (7.6) | 31 (9.2) | 6.0 |
| Chronic pulmonary disease, n (%) | 20 (6.6) | 30 (8.8) | 8.2 |
| Cerebrovascular disease, n (%) | 17 (5.6) | 16 (4.6) | 4.8 |
| Rheumatologic disease, n (%) | 6 (2.0) | 6 (1.7) | 2.0 |
| Comorbidities of interest, n (%) | |||
| ≥ 1 CRAB symptom | 172 (57.0) | 200 (58.6) | 3.3 |
| Anemia | 113 (37.2) | 126 (37.1) | 0.3 |
| Skeletal‐related events | 89 (29.4) | 91 (26.7) | 5.9 |
| Renal impairment e | 36 (12.0) | 46 (13.4) | 4.4 |
| Hypercalcemia | 30 (9.9) | 42 (12.3) | 7.7 |
| Thyroid disease | 33 (11.0) | 40 (11.8) | 2.5 |
| Secondary malignancy | 31 (10.2) | 33 (9.6) | 2.2 |
| Inflammatory conditions f | 9 (2.9) | 7 (2.1) | 5.0 |
Abbreviations: CCI, Charlson Comorbidity Index; CRAB, calcium elevation, renal insufficiency anemia, and bone abnormalities; DRd, daratumumab, lenalidomide, and dexamethasone; ISS, International Staging System; SD, standard deviation; Std. Diff, standardized difference; US, United States; VRd, bortezomib, lenalidomide, and dexamethasone.
denotes variables that were included as part of the doubly robust adjustment in the Cox proportional hazards model.
Inverse probability of treatment weights were estimated using a multivariable logistic regression model with the following baseline covariates: age, gender, race, US region, insurance coverage, index year, ISS stage, selected Quan–CCI comorbidities (shown in Table 1), and additional comorbidities of interest (shown in Table 1, except anemia, skeletal‐related events, and renal impairment).
The proportions displayed were calculated prior to the rounding and may be slightly different than if they were calculated based on rounded numbers.
Other race categories included American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Multiple Race, Hispanic, and Other.
Only Quan–CCI comorbidities that were included in the inverse probability of treatment weighting were included in this table.
Renal impairment was based on diagnostic codes for acute kidney failure or an encounter for care involving renal dialysis.
Inflammatory conditions included psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and systemic lupus erythematosus.